Last updated: July 9, 2026
Boehringer Ingelheim Pharmaceuticals v. Lupin (1:21-cv-00530) Litigation Summary and Patent/Exclusivity Analysis
Executive summary: Boehringer Ingelheim Pharmaceuticals Inc. sued Lupin Ltd. (D. Del.) over an FDA generic application described in the complaint as seeking approval to market a Boehringer-branded product containing the company’s proprietary active ingredient prior to the expiration of Boehringer’s listed patent rights. The case is docketed as 1:21-cv-00530 and reflects a typical Hatch-Waxman patent dispute posture (injunction and damages claims tied to alleged Paragraph IV filings). The record below synthesizes the litigation posture and the business exposure points that follow from the infringement theories, the patent coverage expected to be at issue (listed Orange Book patents, including likely formulation, composition, and/or method-of-use claims), and the generic entry timing risk created by the timing of the district court and any related appeal.
What is the case 1:21-cv-00530 between Boehringer Ingelheim and Lupin about?
Direct answer (litigation posture): This is a Hatch-Waxman ANDA patent infringement action brought by Boehringer Ingelheim Pharmaceuticals Inc. against Lupin Ltd. in the U.S. District Court for the District of Delaware (case number 1:21-cv-00530). The dispute centers on Lupin’s attempt to obtain FDA approval for a generic version of a Boehringer drug while challenging or preparing to challenge Boehringer’s Orange Book–listed patents, typically via a Paragraph IV certification (as reflected by the structure of Hatch-Waxman complaints).
What the litigation usually alleges in this posture:
- Lupin filed an ANDA referencing Boehringer’s NDA.
- Lupin included certifications asserting Boehringer’s listed patents are invalid and/or not infringed.
- Boehringer asserted infringement of one or more listed patents and sought remedies including injunctive relief and damages.
Court and procedural posture to map to exclusivity and entry risk:
- Venue: District of Delaware, a common forum for ANDA patent litigation.
- Case type: Patent infringement under 35 U.S.C. § 271(e)(2) tied to an ANDA submission.
Business relevance: The case drives:
- whether Lupin can launch at risk or is barred by an injunction, and
- whether Boehringer’s asserted patent claims survive validity challenges (invalidity and non-infringement).
Which patents did Boehringer Ingelheim assert in Boehringer v. Lupin 1:21-cv-00530?
Direct answer: The specific asserted patent list is not included in the information provided in the request.
What the asserted set typically looks like in these Delaware ANDA actions:
- One “core” patent covering the active ingredient composition (compound or composition of matter), or
- a formulation or solid state patent covering a specific drug product, or
- a method-of-use patent covering a labeled therapeutic regimen, dosing, or patient subset.
How this determines litigation outcomes:
- If the asserted patents are composition/formulation patents, validity attacks often focus on anticipation/obviousness and written description/enablement.
- If method-of-use patents are asserted, infringement hinges on label-driven evidence: proposed Lupin labeling and prescribing practices.
Actionable lens for deal and risk modeling:
- If Boehringer’s asserted patents include at least one composition/formulation patent, the generic entry depends on a validity win for Lupin or a narrow non-infringement finding.
- If the asserted set is mostly method-of-use, the case outcome can hinge on labeling carve-outs and design-around formulations.
What is the litigation timeline for Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. 1:21-cv-00530?
Direct answer: A timeline with docket dates (complaint filing date, answer, Rule 16 scheduling order, claim construction, summary judgment, trial dates, and post-judgment motions) is not present in the request content.
How to interpret the typical milestone sequence for Hatch-Waxman cases in D. Del.:
- Complaint filed after ANDA submission with Paragraph IV certifications.
- Lupin files an answer asserting non-infringement/invalidity.
- Court sets scheduling order, often including:
- claim construction,
- summary judgment deadlines,
- expert disclosures,
- Daubert motions, and
- trial if the case is not resolved early.
- If Boehringer or Lupin obtains a dispositive ruling, the case can settle or be appealed.
Business exposure points by milestone:
- Early: settlements are common once claim construction narrows claim interpretation.
- Mid-stage: summary judgment on invalidity/non-infringement can create predictable launch timing.
- Late: injunction risk crystallizes; launch “at risk” becomes a board-level decision for the generic maker.
What did Boehringer argue about infringement in 1:21-cv-00530?
Direct answer: The factual infringement theory is not included in the request content.
Typical infringement framework Boehringer uses in Hatch-Waxman filings:
- Compare Lupin’s proposed ANDA product (as described in certifications, product specs, and labeling) against each asserted claim element.
- Use claim construction to map:
- each structural limitation (for composition/formulation patents), or
- each dosage/patient/labeled condition (for method-of-use patents).
How infringement mapping impacts outcomes:
- A narrow construction on key limitations can drive non-infringement.
- Overbroad construction can drive summary judgment for Boehringer.
How did Lupin attack Boehringer’s patents (invalidity and non-infringement) in 1:21-cv-00530?
Direct answer: The specific invalidity arguments and references are not available in the request content.
Typical invalidity attack patterns in these cases:
- Anticipation using prior art publications and patents.
- Obviousness combining known elements.
- Written description/enablement and prosecution history estoppel.
- For formulation patents: prior art teaching the same crystalline form, excipients, ratios, or manufacturing process.
Why this matters commercially:
- If prior art is strong on anticipation/obviousness, the case shifts quickly toward settlement or a post-claim-construction invalidity pathway.
- If Lupin’s case is strongest on non-infringement due to labeling/product differences, Boehringer’s best lever is claim scope.
Were there settlements, injunction rulings, or consent judgments in 1:21-cv-00530?
Direct answer: Settlement terms or any injunction/consent judgment outcomes are not provided in the request content.
What to look for in outcomes (high-intent operational relevance):
- “Carve-out” settlement dates tied to specific Orange Book patents.
- Licensing triggers tied to dismissal of some claims and continued validity challenges for others.
- “At-risk” language indicating launch can occur before final appellate resolution.
What is the FDA and Orange Book exclusivity posture linked to this litigation?
Direct answer: The Orange Book listing details tied to the asserted patents are not included in the request content.
How exclusivity interacts with the infringement case:
- Hatch-Waxman litigation does not eliminate statutory exclusivity; it determines whether the generic can launch before patent expiry.
- If patents expire later than regulatory exclusivity, the patent estate dominates entry timing.
Commercial modeling points that come directly from this interaction:
- Market exclusivity can expire earlier, but patent injunction risk can still prevent launch.
- A win by Lupin on all asserted patents can permit earlier entry, subject to labeling and regulatory constraints.
How does this case compare with other Delaware ANDA patent disputes against Lupin?
Direct answer: A cross-case comparison requires data from other Lupin ANDA litigations not included in the request content.
General comparative patterns (useful for risk framing in this docket type):
- Similar defenses across Lupin cases: invalidity via prior art combinations and narrow construction on claim limitations.
- Similar remedies sought by branded NDA holders: bar on FDA approval until patent expiry or full adjudication.
Key takeaways for investors, BD, and regulatory strategy
- The docket 1:21-cv-00530 is a Hatch-Waxman ANDA patent infringement dispute between Boehringer Ingelheim Pharmaceuticals Inc. and Lupin Ltd. in Delaware, structured around Paragraph IV-type challenges to listed Boehringer patents.
- The case meaningfully impacts generic launch timing by determining whether Lupin can clear the asserted patent barrier through invalidity/non-infringement or whether an injunction delays entry.
- The business outcome is highly dependent on:
- the identity and claim scope of asserted Orange Book patents, and
- the court’s claim construction and dispositive rulings.
- Without the asserted patent list and docket outcomes, a definitive expiration and launch scenario cannot be stated from the request content.
FAQs
What type of lawsuit is 1:21-cv-00530?
A Hatch-Waxman ANDA patent infringement action under 35 U.S.C. § 271(e)(2) in the District of Delaware, brought by Boehringer Ingelheim Pharmaceuticals Inc. against Lupin Ltd.
What drives the injunction risk in Boehringer v. Lupin cases?
The court’s determination on whether Lupin’s proposed generic infringes and whether Boehringer’s asserted Orange Book patents are valid.
Does Orange Book listing control the timing of generic launch?
Yes. Listed patents can trigger an automatic litigation-based barrier and can support injunctive relief even if regulatory exclusivity periods end earlier.
Can Lupin launch “at risk” if the case isn’t final?
That depends on the procedural status and any injunctions or stays issued by the court, none of which are provided in the request content.
What matters most for method-of-use vs formulation patents?
Method-of-use claims hinge on proposed labeling and claimed therapeutic regimen, while formulation/compound patents hinge on product composition, structure, and manufacturing-related limitations.
References (APA)
- Case docket: Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd., 1:21-cv-00530, U.S. District Court for the District of Delaware.
